Therefore, it is plausible that individuals who are homozygous or show compound heterozygosity for each of the minor alleles of these 60 pathogenetic variants will likely have lower levels of in vivo DNase I activity than individuals with other genotypes, thus being at potential risk of developing autoimmune dysfunction such as SLE. The gene discussed is DNASE1; the disease is systemic lupus erythematosus.